| Ma, Ding |
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
|
|
| Active, not recruiting | 3 | 229 | RoW | Olaparib 300mg tablets | AstraZeneca | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive | 12/24 | 12/24 | | |
BGB-290-302, NCT03519230: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer |
|
|
| Active, not recruiting | 3 | 224 | RoW | Pamiparib capsule, BGB-290, Placebo capsule | BeiGene | Ovarian Cancer | 06/25 | 06/26 | | |
|
|
NCT04590599: A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy |
|
|
| Completed | 2 | 205 | RoW | IBI310, Placebo, Sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Cervical Cancer | 11/23 | 11/23 | | |
NCT05325229: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer |
|
|
| Recruiting | 2 | 94 | RoW | Docetaxel for injection (Albumin-bound), Bevacizumab | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Recurrent Ovarian Cancer | 12/24 | 12/24 | | |
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 1048 | RoW | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Hansoh BioMedical R&D Company | Advanced Solid Tumors | 04/26 | 04/28 | | |
| Lei, Ting |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 204 | RoW | Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Aneurysm | 10/24 | 04/25 | | |
| Wang, Peng |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Active, not recruiting | 3 | 407 | Europe, US, RoW | IO102-IO103, Pembrolizumab | IO Biotech, Syneos Health, Merck Sharp & Dohme LLC | Metastatic Melanoma, Unresectable Melanoma | 07/25 | 09/27 | | |
| Recruiting | 2 | 332 | Europe, Canada, Japan, US, RoW | disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 11/26 | 05/28 | | |
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma |
|
|
| Recruiting | 1 | 15 | US | Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib | Ruta Arays, Novartis, National Cancer Institute (NCI) | Metastatic Melanoma, BRAF Gene Mutation | 12/26 | 03/27 | | |
| li, hongyi |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Yuan, Xianglin |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Shu, Chang |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04275323: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
|
|
| Completed | 3 | 302 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 06/24 | 06/24 | | |
| Completed | 3 | 242 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 12/23 | 12/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06000956: A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo |
|
|
| Recruiting | 3 | 408 | RoW | Jitongning tablets, a simulated agent of Jitongning tablets | Tasly Pharmaceutical Group Co., Ltd | Ankylosing Spondylitis | 12/26 | 12/26 | | |
| Recruiting | 2 | 62 | RoW | ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w | Abbisko Therapeutics Co, Ltd | Hepatocellular Carcinoma | 07/24 | 10/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
PATENCY, NCT03767777: Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY（） |
|
|
| Enrolling by invitation | N/A | 150 | RoW | Artery Stent Graft System | Lifetech Scientific (Shenzhen) Co., Ltd. | Thoracic Aortic Dissection | 06/21 | 12/25 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT05126446: the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration |
|
|
| Active, not recruiting | N/A | 120 | RoW | the Aorta Arch Stent Graft System combined with the Endovascular Needle System | Lifetech Scientific (Shenzhen) Co., Ltd. | Aortic Dissection | 10/27 | 03/28 | | |
NCT06520774: Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases |
|
|
| Not yet recruiting | N/A | 103 | NA | Concave Supra-arch Branched Stent-Graft System | Lifetech Scientific (Shenzhen) Co., Ltd., Second Xiangya Hospital of Central South University | Aortic Arch Aneurysm, Penetrating Aortic Ulcer | 10/27 | 10/31 | | |
| Chen, Yuan |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
| Liu, Aiguo |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
NCT05997602: To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH |
|
|
| Recruiting | 2 | 56 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Langerhans Cell Histiocytosis, LCH | 07/24 | 07/26 | | |
NCT05701306: APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors |
|
|
| Recruiting | 1 | 100 | RoW | APG-115, APG-2575 | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Neuroblastoma, Solid Tumor | 06/26 | 12/27 | | |
| Gao, Qinglei |
NCT06123884: BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer |
|
|
| Not yet recruiting | 2/3 | 526 | RoW | Recombinant humanized anti-PD-1 monoclonal antibody injection, BAT1308 injection, Cisplatin, Shunbo, Bevacizumab Injection, Pobevcy, carboplatin, Bobei, Paclitaxel for Injection, Tesu | Bio-Thera Solutions | Cervical Cancer | 04/24 | 08/24 | | |
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer |
|
|
| Recruiting | 1/2 | 54 | RoW | Bevacizumab； HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Recurrent Ovarian Cancer | 10/25 | 10/25 | | |
| Qiu, Hong |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
| Chu, Qian |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06498479: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 460 | RoW | HS-20093, Topotecan | Hansoh BioMedical R&D Company | Small Cell Lung Cancer | 09/26 | 05/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
| Recruiting | 1/2 | 127 | RoW | TQB2618 injection and TQB2450 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| ZHAO, Jianping |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
NCT04462185: A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers |
|
|
| Recruiting | N/A | 3000 | RoW | A genomic and transcriptomic landscape analysis | AnchorDx Medical Co., Ltd., The First Affiliated Hospital of Guangzhou Medical University, Tongji Hospital, Qilu Hospital of Shandong University, Shanghai Zhongshan Hospital, West China Hospital, Beijing Chao Yang Hospital, Johnson & Johnson (China) Investment Ltd. | Pulmonary Nodules | 06/24 | 12/24 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
| Liu, Kai |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
COOPERATION, NCT04912518: Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 250 | RoW | Dexmedetomidine (DEX), Placebo (Saline) | Harbin Medical University, Yangtze River Pharmaceutical Group Co., Ltd. | ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection | 12/24 | 12/25 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
| Shang, Ke |
| No trials found |
